Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer

Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer

Objective: Recent randomized phase III trial has shown significant benefit in overall survival (OS) for patients with advanced cervical cancer by adding bevacizumab to conventional chemotherapy. The aim of this study was to evaluate the prognostic impact for Japanese recurrent, persistent, or metast...

Full description

Bibliographic Details
Main Authors:	Masafumi Yasunaga, Hideaki Yahata, Kaoru Okugawa, Mototsugu Shimokawa, Yumiko Maeda, Emiko Hori, Keisuke Kodama, Hiroshi Yagi, Tatsuhiro Ohgami, Ichiro Onoyama, Kazuo Asanoma, Kiyoko Kato
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Series:	Taiwanese Journal of Obstetrics & Gynecology
Subjects:	Bevacizumab Carboplatin Drug therapy Prognosis Uterine cervical neoplasms
Online Access:	http://www.sciencedirect.com/science/article/pii/S1028455922002133

Similar Items

Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
by: Madison R. Klavans, et al.
Published: (2020-11-01)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
by: Hirotoshi Yasui, et al.
Published: (2014-08-01)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
by: Schuette W, et al.
Published: (2017-11-01)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
by: Toshinobu Hayashi, et al.
Published: (2021-01-01)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
by: Ahmed Gamal Elsayed, et al.
Published: (2017-08-01)

Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
by: Hamid Attarian, et al.
Published: (2009-07-01)

Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
by: Hamid Attarian, et al.
Published: (2009-09-01)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
by: Zhenhua Du, et al.
Published: (2015-07-01)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
by: Yin Tao, et al.
Published: (2022-03-01)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
by: Go Makimoto, et al.
Published: (2014-01-01)

Fibronectin mediates activation of stromal fibroblasts by SPARC in endometrial cancer cells
by: Sachiko Yoshida, et al.
Published: (2021-02-01)

Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models
by: Yanxiu Guo, et al.
Published: (2018-01-01)

Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
by: Yuri Nakao, et al.
Published: (2020-04-01)

Successful avatrombopag combined with cyclosporine treatment for carboplatin/pegylated liposomal doxorubicin/bevacizumab-induced acquired amegakaryocytic thrombocytopenia in a patient with recurrent ovarian cancer: case report
by: Weikang Meng, et al.
Published: (2024-02-01)

Inflammation of Actinic Keratoses Induced by Combination of Carboplatin and Paclitaxel: Two Case Reports
by: Špela Šuler Baglama, et al.
Published: (2022-12-01)

Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer
by: Mohammad Mobayed, et al.
Published: (2009-11-01)

A case of metastatic basal cell carcinoma treated with carboplatin and paclitaxel
by: Chryssoula Papageorgiou, et al.
Published: (2023-01-01)

Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy
by: Melek Kandemir, et al.
Published: (2015-12-01)

Metastatic ameloblastoma with postoperative accelerated tumor growth treated with carboplatin and paclitaxel: a case report
by: Joo Un Park, et al.
Published: (2022-03-01)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
by: Katsurada N, et al.
Published: (2020-02-01)

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports
by: Ping-Chih Hsu, et al.
Published: (2023-01-01)

Paclitaxel plus Carboplatin Chemotherapy for Primary Peritoneal Carcinoma: A Study of 22 Cases and Comparison with Stage III–IV Ovarian Serous Carcinoma
by: R. Kawaguchi, et al.
Published: (2012-04-01)

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)
by: Ticiana A. Leal, et al.
Published: (2022-11-01)

Long‐term survival of a patient with refractory advanced adrenocortical carcinoma after combination chemotherapy with paclitaxel and carboplatin plus mitotane
by: Yuki Kobayakawa, et al.
Published: (2022-07-01)

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
by: Yuri Ueda, et al.
Published: (2020-10-01)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
by: Shimokawa M, et al.
Published: (2022-09-01)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
by: Kunihiko Funaishi, et al.
Published: (2017-06-01)

Irreversible laryngeal palsy: An induced complication of carboplatin 450mg/m2 and paclitaxel 250mg/m2 - Case report
by: Rawish Kumar, et al.
Published: (2018-03-01)

Advanced papillary serous carcinoma of the uterine cervix: a case with a remarkable response to paclitaxel and carboplatin combination chemotherapy
by: Tomoyuki Shirase, et al.
Published: (2012-01-01)

Comparison of Antiemetic Effects of Ondansetron Granisetron and Tropisetron For Acute Emesis In Ovarian Cancer Patients Receiving Chemotherapy With Paclitaxel and Carboplatin
by: Taner Turan, et al.
Published: (2007-08-01)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
by: Shinichi Tate, et al.
Published: (2021-02-01)

rare cause of recurrent haemolytic anaemia: carboplatin and paclitaxel-induced autoimmune haemolytic anaemia
by: Pitchaporn Yingchoncharoen, et al.
Published: (2023-02-01)

THE DIFFERENCES OF APOPTOSIS EFFECTS BETWEEN COMBINATION OF MELOXICAM WITH GEMCITABINE-CARBOPLATIN CHEMOTHERAPY COMPARED TO GEMCITABINE-CARBOPLATIN CHEMOTHERAPY ALONE IN UROTHELIAL CARCINOMA CULTURE CELLS
by: Ananta Cahyo Nugroho, et al.
Published: (2019-01-01)

A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer
by: Walburga Engel-Riedel, et al.
Published: (2018-02-01)

Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study
by: Naoya Ikeda, et al.
Published: (2022-05-01)

Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
by: Hye Sook Chon, et al.
Published: (2017-06-01)

COMPARISON BETWEEN GEMCITABINE-CARBOPLATIN AND COMBINATION OF GEMCITABINE-CARBOPLATIN AND CELECOXIB IN UROTHELIAL CARCINOMA CELL APOPTOSIS
by: Widya Sakti Pratama, et al.
Published: (2019-01-01)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
by: Yingkai Chen, et al.
Published: (2022-06-01)

The Comparison of Neutropenia and Peripheral Neuropathy Condition as an Impact of 3-hours and 24-hour Paclitaxel Infusion of Paclitaxel-Carboplatin Chemotherapy on Ovarian Cancer Patients
by: Primandono Perbowo, et al.
Published: (2019-07-01)

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
by: Jun Sugisaka, et al.
Published: (2023-11-01)